Every “Bard Hernia Mesh Point System” Chart Online Cites No Court Document. Bard’s Parent Filed Its Own Numbers 15 Days Ago — and Pending Claims Went Up, Not Down

Becton Dickinson, which owns C.R. Bard and Davol, is a public company. It has to tell the SEC about this litigation four times a year, under penalty of securities law. Its most recent Form 10-Q was filed August 6, 2026, covering the quarter ended June 30, 2026. It is fifteen days old and it is free to read.

Here is the operative sentence, verbatim:

“As of June 30, 2026 and September 30, 2025, the Company was defending approximately 7,090 and 6,905, respectively, product liability claims involving its line of hernia repair devices (collectively, the ‘Hernia Product Claims’).”

Read that twice. Nine months into a settlement that was supposed to resolve the vast majority of the hernia inventory, the number of claims the company is defending rose by 185. That is the opposite of the wind-down every “2026 payout timeline” article describes.

The same paragraph dates the deal more precisely than the press coverage does. BD says it entered the settlement agreement “in the fourth quarter of fiscal year 2024” — and BD’s fiscal year ends September 30, so that means July through September 2024, before the October 2024 headlines that most sites cite as the start date. It also says the amounts “will be paid out over a multi-year period.” Not this year. Over years.

And one more line that quietly contradicts a great deal of what is being published: “There are no trials currently scheduled.”

The reason no verified point schedule exists is structural, and once you see it the whole genre of “Bard payout chart” content falls apart.

This is not a class action. It is an aggregate settlement negotiated privately between a defendant and plaintiffs’ law firms, with each claimant deciding individually whether to accept. In a class action, the allocation plan is a court document: it gets filed, approved by a judge, and posted on a court-authorized website that anyone can read. That is precisely why we can tell you, on a different case published the same day as this one, exactly how the Wells Fargo ESOP settlement divides its $84 million — fourteen dividend dates, weighted by holdings, with a $10 minimum. The court made that public.

Bard has no equivalent. The hernia claims sit in a coordinated proceeding in Rhode Island State Court and in MDL No. 2846 — In re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation, 2:18-md-2846 in the Southern District of Ohio, before Judge Edmund A. Sargus, Jr. and Magistrate Judge Kimberly A. Jolson — plus other state and federal courts and multiple putative class actions in Canada.

The Southern District of Ohio publishes a curated list of MDL 2846 orders on its own website, organized by classification. The categories are dispositive motions, case management, discovery and pretrial orders. There is no settlement allocation order, no point schedule and no payout matrix among them.

BD says why, in its own filing. Describing its settlement activity generally, the company writes that these efforts “have resulted in confidential settlements and going forward could result in further settlements, the terms of which may be confidential.” Confidential is not a gap in the public record waiting to be filled by a blog. It is the design.

You will see a billion-dollar number attached to the Bard hernia settlement almost everywhere. BD’s filing does contain a figure in that range — and it does not mean what those pages say it means.

What BD actually discloses is this: accruals for the company’s product liability claims and certain other legal matters, including legal defense costs, amounted to approximately $1.6 billion at June 30, 2026, down from approximately $1.8 billion at September 30, 2025.

That single accrual covers hernia mesh and pelvic mesh and inferior vena cava filters and implantable ports and other matters and the lawyers defending all of them. BD does not break out a hernia-only settlement amount anywhere in the filing. Anyone dividing a billion-dollar figure by a claim count to produce a per-claimant average is dividing the wrong numerator by an unrelated denominator.

One more distinction worth having, because it is being actively conflated. BD does report upcoming trials — August 18, 2026 and October 13, 2026 — but those are in the implantable port litigation, roughly 3,850 claims in an MDL in the District of Arizona, where an April 2026 trial produced a defense verdict on two claims and a mistrial on two others. Those dates have nothing to do with hernia mesh. For hernia, the filing’s words remain: no trials currently scheduled.

If you have a hernia mesh case, the person who can tell you your number is your own attorney, because your settlement terms are contractual and confidential, and they vary by firm, by injury, by product and by the inventory your firm negotiated. That is an unsatisfying answer and it is the true one.

What the public record supports is narrow and worth holding onto:

• A settlement exists, was entered by September 30, 2024, covers the vast majority of BD’s then-existing hernia litigation, and pays over multiple years.
• Claims are still being filed — the pending count rose from 6,905 to 7,090 over nine months — so the litigation is not closed.
• No public document sets out points, tiers or per-point dollar values, and the company states its settlement terms may be confidential.
• There are no hernia trials on the calendar, which removes the usual public-verdict source of valuation data.

A note on the numbers you will see quoted elsewhere. BD’s 7,090 is the count of claims the company is defending, which is not the same measure as cases pending on the MDL 2846 docket, which in turn is not the same as the total claims covered by a settlement including unfiled ones. Those three figures legitimately differ by an order of magnitude — which is exactly why so many sites can each quote a different number and all sound confident. We are reporting the one measure whose definition and date we can point to. We did not independently verify a current MDL docket count and are not quoting one.